Clinical and Translational Gastroenterology最新文献

{"title":"Non-invasive fibrosis tests in Wilson Disease: Insights from the international Wilson Disease Registry and Barcelona Cohort.","authors":"Frederik Teicher Lauridsen Kirk, Zoe Mariño, Uyen Kim To, Asim Ulcay, Hatice Maras, Sefa Keserci, Kaitlin Maciejewski, Isabelle Mohr, Regino P González-Peralta, Sanjiv Harpavat, Sabela Lens, María-Carlota Londoño, Sihoun Hahn, Thomas Damgaard Sandahl, Yanhong Deng, Alba Diaz, Michael L Schilsky","doi":"10.14309/ctg.0000000000001121","DOIUrl":"https://doi.org/10.14309/ctg.0000000000001121","url":null,"abstract":"<p><strong>Introduction: </strong>Non-invasive tests (NITs) accurately detect fibrosis and may reduce the need for liver biopsy (LB). Detection of advanced fibrosis (≥F3) is clinically important for prognosis, but few studies have explored the use of NITs in patients with Wilson Disease (WD).</p><p><strong>Methods: </strong>In this multicentre observational study, adult and pediatric WD patients from seven international expert centers with histologic fibrosis staging were included. NITs (Transient elastography (TE), Fibrosis-4 index (FIB-4), AST to platelet-ratio (APRI), Steatosis-associated fibrosis estimator (SAFE), and NAFLD fibrosis score (NFS)) and clinical data were collected. NITs were compared with liver biopsy (LB) to detect advanced fibrosis (≥F3).</p><p><strong>Results: </strong>In total, 123 patients were included: median age was 30 years (IQR 17.4, 43.1); time from WD diagnosis to LB was 6.7 months (0.7, 144.1); 30.9% had advanced fibrosis (≥F3), while concomitant metabolic risk factors (obesity and diabetes) were rare. Overall, 64 patients had NITs measured within 1 year of the LB and constituted the primary analysis group. All NITs, except FIB-4, were significantly elevated in patients with ≥F3. TE had the best overall accuracy (AUC=0.79), and performed well at an optimized cut-off of ≥8.35 kPa (sens=0.88, spec=0.85). APRI had lower accuracy, but effectively ruled out ≥F3 at the optimized cut-off of ≥1.3 (AUC=0.71, sens=0.38, spec=1.00). Combining those into a score (APRITE) achieved an AUC of 0.88.</p><p><strong>Discussion: </strong>TE demonstrated good diagnostic performance for identifying advanced fibrosis in WD. APRI showed high specificity, while the exploratory APRITE score showed encouraging performance.</p>","PeriodicalId":10278,"journal":{"name":"Clinical and Translational Gastroenterology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149227453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunoglobulin G and liver stiffness in autoimmune hepatitis: Timing matters more than biochemical correction.","authors":"Sebastian Niezen, Daniela Goyes, Victoria Abadi-Ron, Natalia Rojas Amaris, Fernando Munguia, Ana Marenco-Flores, Behnam Saberi, Vilas Patwardhan, Alan Bonder","doi":"10.14309/ctg.0000000000001120","DOIUrl":"https://doi.org/10.14309/ctg.0000000000001120","url":null,"abstract":"<p><strong>Objectives: </strong>Transient elastography may overestimate fibrosis in autoimmune hepatitis (AIH) because hepatic inflammation independently increases liver stiffness measurement (LSM). We aimed to determine which inflammation markers confound LSM in AIH, whether algebraic correction improves accuracy, and when LSM becomes reliable for fibrosis staging.</p><p><strong>Methods: </strong>Single-center retrospective cohort of adults with AIH, paired diagnostic Metavir biopsy, and at least one FibroScan visit with same-visit alanine aminotransferase (ALT) and immunoglobulin G (IgG). Mixed-effects linear regression modeled LSM on biopsy stage, ALT, IgG, and time since diagnosis with a patient-level random intercept. An inflammation-adjusted LSM was computed by subtracting estimated ALT and IgG contributions. Spearman correlation and DeLong-tested AUROC for advanced fibrosis (F3-F4) compared measured and adjusted LSM, stratified by inflammation state and treatment timing.</p><p><strong>Results: </strong>We analyzed 208 FibroScan observations from 119 AIH patients (49 with advanced fibrosis). IgG was independently associated with LSM (β = +0.003 kPa per mg/dL, p < 0.001) while ALT was not (β ≈ 0, p = 0.68). The IgG-LSM relationship varied by treatment timing (IgG × 0-6 months interaction p = 0.001; IgG × 12-24 months p = 0.004). Algebraic correction did not improve discrimination (full-cohort AUROC measured 0.76 vs adjusted 0.72, DeLong p = 0.18). LSM accuracy for advanced fibrosis varied by timing: AUROC 0.71 pretreatment (n = 35), 0.64 at 12-24 months (n = 22), and 0.83 beyond 24 months (n = 72).</p><p><strong>Conclusions: </strong>In AIH, IgG-not ALT-independently inflates LSM, with a time-dependent effect strongest early after diagnosis. Algebraic correction did not improve fibrosis discrimination, but LSM accuracy improved substantially beyond 24 months after AIH diagnosis. Timing rather than algebraic correction is the more actionable clinical strategy for FibroScan interpretation in AIH.</p>","PeriodicalId":10278,"journal":{"name":"Clinical and Translational Gastroenterology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149191741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term Benefits of Mirikizumab on Patient-Reported Outcomes in Individuals with Crohn's Disease: 2-Year Results from the VIVID-2 Extension Study.","authors":"Minhu Chen, Ailsa Hart, Aisha Vadhariya, Yiying Brogan, Wai Man Maria Chan, Richard E Moses, Na Lu, Ashwin Ananthakrishnan, Sarah C Glover, Millie Long, Lisa Malter, Peter Bossuyt, Jessica R Allegretti","doi":"10.14309/ctg.0000000000001119","DOIUrl":"https://doi.org/10.14309/ctg.0000000000001119","url":null,"abstract":"<p><strong>Background: </strong>Mirikizumab, an anti-IL-23p19 monoclonal antibody, has demonstrated clinical efficacy in Crohn's disease (CD), improving symptoms and quality of life (QoL) over one year in the VIVID-1 trial. This analysis from the VIVID-2 open-label extension evaluated its long-term impact on CD symptoms and QoL at two years.</p><p><strong>Methods: </strong>Patients from VIVID-1 with an endoscopic response continued mirikizumab (300 mg subcutaneous) in VIVID-2. Endoscopic non-responders at 52 weeks underwent re-induction, then maintenance therapy. QoL was assessed at Weeks 64 and/or 104 using the Inflammatory Bowel Disease Questionnaire (IBDQ), EQ-5D-5L visual analog scale (VAS), and work productivity by Work Productivity and Activity Impairment: Crohn's Disease (WPAI:CD) questionnaire. Other patient-reported outcomes (PRO) assessed were fatigue (FACIT-Fatigue), abdominal pain (AP), stool frequency (SF), and clinical remission by PRO (AP ≤1 and SF ≤3, no worsening from baseline). Missing data were handled with modified non-responder imputation for categorical outcomes, and baseline observation carried forward for continuous outcomes. Analysis of covariance was used to estimate mean changes from baseline.</p><p><strong>Results: </strong>At 104 weeks, 85.0% of VIVID-1 endoscopic responders and 72.6% endoscopic non-responders achieved IBDQ response, while 71.3% endoscopic responders and 60.8% endoscopic non-responders achieved IBDQ remission. By Week 64, EQ-5D-5L VAS scores improved by 22-27 points, WPAI decreased by 14-34 points, and >60% patients achieved meaningful improvement in fatigue. Approximately 75% responders and 54% non-responders achieved clinical remission by PRO at two years.</p><p><strong>Conclusion: </strong>Long-term mirikizumab treatment led to sustained QoL improvements and reduced symptoms in patients with CD, regardless of their endoscopic response status.</p>","PeriodicalId":10278,"journal":{"name":"Clinical and Translational Gastroenterology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149179475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between Crohn's disease and pulmonary nodule patterns: an inverse probability-weighted analysis of real-world data.","authors":"Changsheng Cai, He Gu, Chunyan Li, Jie Liang, Feng Tian, Xiaocang Cao, Yue Li, Yubei Gu, Wenbin Qin, Qi Feng, Jun Shen","doi":"10.14309/ctg.0000000000001118","DOIUrl":"https://doi.org/10.14309/ctg.0000000000001118","url":null,"abstract":"<p><strong>Background: </strong>Crohn's disease (CD) is a systemic inflammatory disorder with potential pulmonary involvement; however, its association with pulmonary nodules and how disease phenotype, medication, and inflammation affect nodule characteristics are unclear. Using real-world data, we aimed to comprehensively assess the burden of pulmonary nodules among patients with CD, characterize their longitudinal dynamic trajectories, and identify key determinants of their imaging phenotypes.</p><p><strong>Methods: </strong>In this retrospective multicenter cohort study of 2,009 patients with CD and 4,002 controls, we used inverse probability weighting (IPW) to compare the nodule burden and its dynamics over time in a longitudinal subcohort (n = 2,956). We assessed the associations of the Montreal classification, biologics, corticosteroids, C-reactive protein, and extraintestinal manifestations with nodule features among patients with CD and explored risk factors for high-risk nodules related to CD.</p><p><strong>Results: </strong>CD was associated with higher nodule counts across all subtypes (e.g., solid nodules: incidence rate ratio [IRR], 1.80; 95% confidence interval [CI], 1.62-1.98; P < 0.001). Longitudinally, compared with controls, patients with CD experienced greater reductions in solid nodules and nodules <6 mm (P < 0.001) despite the slightly faster growth of persistent nodules <6 mm. Disease phenotypes and extraintestinal manifestations were not associated with nodule features. Age was an independent predictor and the strongest predictor of the pulmonary nodule burden. Adalimumab was correlated with fewer non-solid and 6- to 8-mm nodules (IRR, 0.615-0.676; P < 0.01). CD-related clinical factors had limited utility for predicting high-risk nodules.</p><p><strong>Conclusions: </strong>CD confers an increased pulmonary nodule burden with a unique dynamic evolution. Risk stratification should prioritize age and medication exposures instead of disease phenotype because phenotypic markers lack predictive value for nodule outcomes.</p>","PeriodicalId":10278,"journal":{"name":"Clinical and Translational Gastroenterology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149135236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"US Healthcare Professionals' Management of MASH and Knowledge of GLP-1, GIP, and Glucagon Receptor Agonists.","authors":"Harold E Bays, Jonathan Pak, A Sidney Barritt","doi":"10.14309/ctg.0000000000001116","DOIUrl":"https://doi.org/10.14309/ctg.0000000000001116","url":null,"abstract":"<p><strong>Introduction: </strong>Various combinations of agonists of the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR) are in clinical trials for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). We explored how US healthcare professionals (HCPs) treating people with MASLD/MASH perceive these investigational agents.</p><p><strong>Methods: </strong>Respondents to this online survey (November 2024 to January 2025) were specialists in hepatology/gastroenterology (HEP/GASTROs), endocrinology (ENDOs), and primary care (PCCs). The survey assessed awareness of GLP-1R, GIPR, and GCGR pathways, as well as pharmacotherapeutics targeting them.</p><p><strong>Results: </strong>Of 760 respondents, 256 were HEP/GASTROs, 252 were ENDOs, and 252 were PCCs. Ultrasound was the most common imaging technique used to diagnose and assess MASH overall (69.8%); however, HEP/GASTROs most commonly used vibration-controlled transient elastography (71.9%). Only 53.9% and 30.1% of HCPs were \"very\" or \"extremely familiar\" with GIPR and GCGR, respectively, but most (76.8%) HCPs were \"very\" or \"extremely familiar\" with GLP-1R. ENDOs were more likely than either HEP/GASTROs or PCCs to state that activation of GCGR was associated with increased glycogenolysis and gluconeogenesis (59.7% vs 50.0% [P < 0.05] vs 50.2% [P < 0.05]). A total of 90.3%, 75.9%, and 87.0% of respondents expected GLP-1R, GIPR, and GCGR agonists, respectively, to benefit people with MASH.</p><p><strong>Conclusions: </strong>HCPs were generally more familiar with GLP-1R, and the effects of its activation, than with GIPR and GCGR. HCPs anticipate that agonists of these receptors will have meaningful clinical benefits for MASLD/MASH and other cardiometabolic conditions.</p>","PeriodicalId":10278,"journal":{"name":"Clinical and Translational Gastroenterology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149105011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimal Corticosteroid Use in Patients With Severe Alcohol-Associated Hepatitis: A Systematic Review and Meta-Analysis.","authors":"Fatima Elmustafa, Abdelhaleem Sideeg, Mahima Tyagi, Akshaya Srikanth Bhagavathula, Mangesh Pagadala, Juan P Arab, Ashwani K Singal","doi":"10.14309/ctg.0000000000001111","DOIUrl":"https://doi.org/10.14309/ctg.0000000000001111","url":null,"abstract":"<p><strong>Background: </strong>The Lille score is an established tool to guide corticosteroid (CS) response and treatment in severe alcohol-associated hepatitis (AH), MELD score >20. However, its use in clinical trials has remained inconsistent. We performed this meta-analysis to compare mortality and infection rates between studies using Lille-guided versus those using CS not guided by the Lille score.</p><p><strong>Methods: </strong>We performed a systematic review and meta-analysis of randomized controlled trials (2007-2025) evaluating treatment arms using CS in severe AH. Pooled mortality and infection rates at 28, 90, and 180 days were calculated for Lille-guided and non-Lille-guided arms.</p><p><strong>Results: </strong>Fourteen corticosteroid-treated arms from 13 trials (N=1,294) were included, of which four studies (n=437) used CS guided by the Lille score. Mortality was lower in Lille-guided arms compared with non-Lille-guided arms at 28 days: [8 (2-14) vs 21 (13-29)] %, P=0.01, and at 90 days [15 (10-20) vs 40 (25-56)] %, P<0.001, but similar at 180 days [35 (16-54) vs 48 (34-62)] %, P=0.27. Infection rates at corresponding time points were 14 (11-17), 26 (14-38), and 32 (19-44), without differences between Lille- and non-Lille-guided CS arms. Substantial heterogeneity existed across studies, mainly due to differences in the publication year of the 28-day mortality outcome.</p><p><strong>Conclusion: </strong>Lille-guided CS use is associated with lower mortality across follow-up periods without a significant difference in infection rates. These findings support the use of the Lille score to guide CS therapy in patients with severe AH.</p>","PeriodicalId":10278,"journal":{"name":"Clinical and Translational Gastroenterology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preventable Visits to the Emergency Department in Patients with Cirrhosis.","authors":"Swetha Parvataneni, Eric S Orman, Qing Tang, Raj Vuppalanchi, Naga Chalasani, Nicholas Eric Harrison, Archita P Desai","doi":"10.14309/ctg.0000000000001117","DOIUrl":"https://doi.org/10.14309/ctg.0000000000001117","url":null,"abstract":"<p><strong>Background/aims: </strong>Emergency department (ED) utilization is a major driver of healthcare costs in cirrhosis, yet the burden of preventable ED visits (EDVs) is understudied. We aimed to estimate the prevalence of potentially preventable EDVs, associated clinical factors, and outcomes.</p><p><strong>Methods: </strong>In a retrospective cohort study of adults with cirrhosis presenting to a statewide health system in 2021, 2,124 index EDVs were adjudicated for preventability using predefined cirrhosis-specific criteria (preventable with urgent hepatology evaluation, urgent paracentesis, expanded hours of outpatient access, or outpatient medication optimization). LASSO variable selection followed by multivariable logistic regression identified factors independently associated with preventable EDVs.</p><p><strong>Results: </strong>Overall, 15% (n=317) of index ED visits were potentially preventable with an urgent hepatology follow-up (45%), paracentesis access (33%), and outpatient medication management (31%). Compared with non-preventable visits, preventable EDVs had lower 90-day mortality (10% vs 17%; p=0.001) but higher 90-day ED revisits (50% vs 41%; p=0.003). In multivariable analysis, key patient factors associated with preventable EDVs were active alcohol use (aOR 3.05, 95%CI:1.03-9.01, p=0.044), lack of access to primary care (aOR 5.40, 95%CI:1.79 -16.30, p=0.003), and uncontrolled ascites at time of EDV (aOR 2.19, 95%CI:1.45-3.32, p<0.001). A discharge diagnosis of ascites was associated with a preventable EDV (aOR 2.05, 95%CI:1.29-3.25, p=0.002) while diagnoses of GI bleed, electrolyte disorders, infections and non-liver related diagnosis were not associated with preventable EDVs.</p><p><strong>Conclusions: </strong>Potentially preventable EDVs represent 1 in 6 EDVs and are frequently related to timely outpatient specialty access and ascites management suggesting that targeted outpatient care redesign may reduce cirrhosis-related acute healthcare use.</p>","PeriodicalId":10278,"journal":{"name":"Clinical and Translational Gastroenterology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Artificial Intelligence-Based Blood Test using protein and miRNA biomarkers for Colorectal Cancer Screening.","authors":"Lourdes Planelles, Marta Jiménez-Martínez, Carmen Monsalve-Hernando, Sara González-García, Lourdes Castillo, Kamila Janusz, Cristina A Devesa, Nastazja D Pilonis, Rocio Arroyo, Stefan Schubert, Michal F Kaminski","doi":"10.14309/ctg.0000000000001109","DOIUrl":"https://doi.org/10.14309/ctg.0000000000001109","url":null,"abstract":"<p><strong>Introduction: </strong>Colorectal cancer (CRC) is the third most diagnosed cancer worldwide. Only invasive screening methods have been shown to be effective in reducing CRC incidence through the detection of advanced adenomas (AA). This work aimed to develop an Artificial Intelligence (AI)-based blood test for CRC screening and evaluate its diagnostic accuracy.</p><p><strong>Methods: </strong>The test is based on the detection of a protein and miRNA signature and on an AI-derived predictive algorithm. The training/test and validation of the model were conducted analyzing plasma samples from 3,569 participants recruited in two independent prospective clinical studies: a case-control cohort and a screening cohort. Colonoscopy was used as reference. The specificity, sensitivity, predictive value, and likelihood ratio of the test were validated in 2,856 patients from the screening cohort.</p><p><strong>Results: </strong>The test showed 83.3% sensitivity for CRC (95% CI, 58.6 to 96.4) and 65.6% for AA (95% CI, 57.4 to 73.31) at 87.2% specificity (95% CI, 84.9 to 90.1) for no colonoscopy findings, non-neoplastic findings and non-advanced precancerous lesions. The sensitivity to detect CRC and AA located in the proximal colon was 80.0% (95% CI, 28.35 to 99) and 64.5% (95% CI, 52.7 to 75.1), respectively.</p><p><strong>Discussion: </strong>In an average-risk screening population, the test appears to be highly sensitive for detecting CRC and its precursor lesions such as AA and has received Breakthrough Device Designation from the US Food and Drug Administration. These exploratory results will be validated in a pivotal clinical study conducted in a larger US screening cohort. ClinicalTrial.gov registry number: NCT06738511.</p>","PeriodicalId":10278,"journal":{"name":"Clinical and Translational Gastroenterology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to Khan et al.","authors":"M E Delgado, J Benet, I Herrero-Fresneda","doi":"10.14309/ctg.0000000000001112","DOIUrl":"https://doi.org/10.14309/ctg.0000000000001112","url":null,"abstract":"","PeriodicalId":10278,"journal":{"name":"Clinical and Translational Gastroenterology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: Acute and Long-Term Effects of App-Delivered Heartfulness Meditation on Psychological Outcomes and the Endocannabinoid Signaling System in Cyclic Vomiting Syndrome.","authors":"Thangam Venkatesan, Cecilia J Hillard, Lina Iyer, Saranya Arumugam, Stacey Culp, Mahima Vyas, Kebire Gofar, Ana Petrova, Olafur S Palsson","doi":"10.14309/ctg.0000000000001106","DOIUrl":"https://doi.org/10.14309/ctg.0000000000001106","url":null,"abstract":"","PeriodicalId":10278,"journal":{"name":"Clinical and Translational Gastroenterology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}